Cambridge Biotech Serum Western Blot Update; Adaltis U.S. Inc. Grows Their Customer Base for Calypte Product.

Business Editors/Health/Medical Writers

ALAMEDA, Calif.--(BUSINESS WIRE)--April 10, 2003

Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, said today that its decision to establish a distribution relationship with Adaltis U.S. Inc. has opened up new markets for its Cambridge Biotech serum Western blot product, without negatively impacting the Company's direct customers.

Richard Eckloff, Vice President and General Manager, Adaltis U.S. Inc., stated, "Nine months ago we welcomed the opportunity to represent Calypte's serum Western blot product. Today we believe that this was a sound business decision, and we remain committed to continuing to grow this business.

"We are able to offer an established product with an excellent reputation in a category with only one other competitor and have found that many customers and potential accounts consider the quality of the product to be a gold standard. That quality message along with the promise of guaranteed delivery has allowed us to capture in excess of 30 accounts. Also, we have well over 50 prospective accounts and are in discussions with several national reference labs," Eckloff added.

"We are committed to the serum Western blot business and are pleased with the outlook presented by Adaltis," said Nancy Katz, President and CEO for Calypte. "We believe that the guaranteed delivery message used by Adaltis is meaningful to customers since we know that this industry has historically been plagued with extensive backorders. Calypte has established an excellent track record with Adaltis by providing on time delivery of 100% of Adaltis' scheduled orders and we have accomplished this without impacting our direct customers."

Adaltis U.S. Inc. actively distributes and markets the Cambridge Biotech serum Western blot kit via marketing and promotion programs and their sales organization.

About Adaltis U.S. Inc.

Adaltis is an international privately held diagnostic group of companies that develop, manufacture and distribute diagnostic products in select markets. Adaltis U.S. Inc. provides specialized diagnostic products through its direct sales and support organization maintaining a high quality standard of products and services it offers. Adaltis U.S. Inc. is headquartered in Allentown, Pennsylvania.

About Calypte Biomedical

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found on our website at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.